alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 10-6950

LONNIE GETER,

Petitioner – Appellant,

v.

MICHAEL MCCALL, Warden of Perry Correctional Institution,

Respondent – Appellee.

Appeal from the United States District Court for the District of 

South Carolina, at Anderson. Patrick Michael Duffy, Senior 

District Judge. (8:09-cv-01589-PMD)

Submitted: January 28, 2011 Decided: February 15, 2011

Before MOTZ, DUNCAN, and WYNN, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Lonnie Geter, Appellant Pro Se. Donald John Zelenka, Deputy 

Assistant Attorney General, Samuel Creighton Waters, Assistant 

Attorney General, Columbia, South Carolina, for Appellee.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Lonnie Geter seeks to appeal the district court’s 

order accepting the recommendation of the magistrate judge and 

denying relief on his 28 U.S.C. § 2254 (2006) petition. The 

order is not appealable unless a circuit justice or judge issues 

a certificate of appealability. 28 U.S.C. § 2253(c)(1) (2006). 

A certificate of appealability will not issue absent “a 

substantial showing of the denial of a constitutional right.” 

28 U.S.C. § 2253(c)(2) (2006). When the district court denies 

relief on the merits, a prisoner satisfies this standard by 

demonstrating that reasonable jurists would find that the 

district court’s assessment of the constitutional claims is 

debatable or wrong. Slack v. McDaniel, 529 U.S. 473, 484 

(2000); see Miller-El v. Cockrell, 537 U.S. 322, 336-38 (2003). 

When the district court denies relief on procedural grounds, the 

prisoner must demonstrate both that the dispositive procedural 

ruling is debatable, and that the petition states a debatable 

claim of the denial of a constitutional right. Slack, 529 U.S. 

at 484-85. We have independently reviewed the record and 

conclude that Geter has not made the requisite showing. 

Accordingly, we deny a certificate of appealability and dismiss 

the appeal. We dispense with oral argument because the facts 

and legal contentions are adequately presented in the materials 
3

before the court and argument would not aid the decisional 

process.

DISMISSED
# Fourth Court of Appeals **San Antonio, Texas**

October 3, 2018

No. 04

- 18

- 00646

- CV

IN THE INTEREST OF J.A.R. JR., J.R.R. A ND A.I.T

. , From the 131st Judicial District Court, Bexar County, Texas Trial Court No. 2017

- PA

- 02660 Honorable Charles E. Montemayor, Judge Presiding



### ORDER

This is an accelerated appeal of an order terminating the appellant’s parental rights
, which must be disposed of by this court within 180 days of the date the notice of appeal is filed. T EX

. R. J UD

. A DMIN

. 6.2. The reporter’s record was originally due on September 20, 2018. On September 26 , 2018, the court reporter filed a notification of late record request ing an extension of time to file the reporter’s record until October 12, 2018. It is therefore ORDERED that the reporter’s record must be filed in this appeal no later than October 1 2 , 2018

. T EX

. R. A PP

. P. 35.3(c). FURTHER REQUESTS FOR EXTENSIONS OF TIME ARE DISFAVORED.

_________________________________ Sandee Bryan Marion, Chief Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said court on this 3rd day of October, 2018

.

___________________________________ KEITH E. HOTTLE
, Clerk of Court
§ 251.8 Modification or extension of authorized importation programs. ( a ) A supplemental proposal to modify or extend an authorized SIP must be submitted in electronic format via the ESG, or to an alternative transmission point identified by FDA, for FDA's consideration.
( b ) FDA's review and authorization of a supplemental proposal to modify or extend an authorized SIP is governed by this part. In reviewing a supplemental proposal, FDA may take into account information learned subsequent to authorization of the SIP.
( c ) FDA may authorize a supplemental proposal from a SIP Sponsor to add additional Foreign Sellers or additional Importers to an authorized SIP if FDA determines the SIP Sponsor has adequately demonstrated that the SIP has consistently imported eligible prescription drugs in accordance with section 804 of the Federal Food, Drug, and Cosmetic Act and this part. Each supply chain under a SIP must be limited to one manufacturer, one Foreign Seller, and one Importer.
( d ) If FDA authorizes changes to a SIP, the Importer must submit a new Pre-Import Request in accordance with § 251.5.
( e ) A SIP Sponsor must not make any changes or permit any changes to be made to a SIP without first securing FDA's authorization.
( f ) A SIP Sponsor may request that FDA extend the authorization period of an authorized SIP. Such a request must be submitted at least 90 calendar days before the SIP's authorization period will expire. To be eligible for an extension of the authorized SIP, a SIP must be up to date on all of the information and records-related requirements of section 804 of the Federal Food, Drug, and Cosmetic Act and this part. FDA may extend the authorization period for up to 2 years at a time.
§ 522.234 Butamisole. ( a ) *Specifications.* Each milliliter of solution contains 11 milligrams (mg) butamisole hydrochloride.
( b ) *Sponsors.* See Nos. 054771 and 058198 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer 0.1 mg per pound of body weight by subcutaneous injection. In problem cases, retreatment for whipworms may be necessary in approximately 3 months. For hookworms, a second injection should be given 21 days after the initial treatment.
( 2 ) *Indications for use.* For the treatment of infections with whipworms (*Trichuris vulpis*), and the hookworm (*Ancylostoma caninum*).
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16184, Mar. 25, 2014, as amended at 86 FR 14819, Mar. 19, 2021]
IN THE SUPREME COURT OF THE STATE OF MONTANA

RIVERSIDE MOBILE HOME & RV 

PARK, LLC,

Plaintiff/Appellee,

-vsDONALD BULLOCK and CYTHNIA 

BULLOCK,

Defendants/Appellants.

_________________________________

______

)

)

)

)

)

)

)

)

)

)

)

Case No. DA 23-0494

ORDER OF DISMISSAL WITH 

PREJUDICE

Pursuant to the Parties’ Stipulation for Dismissal with Prejudice, and good 

cause appearing;

IT IS HEREBY ORDERED that this matter is dismissed with prejudice, 

with each of the parties to bear its own costs and attorney’s fees.

Electronically signed by:

Mike McGrath

Chief Justice, Montana Supreme Court

November 17 2023

11/17/2023

Case Number: DA 23-0494
EXHIBIT 32.1
 
 CERTIFICATION PURSUANT TO
 PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
 
 In connection with the Quarterly Report on Form 10-Q of Southwall Technologies Inc. (the “Company”), for the quarter ended September 30, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mr. Dennis Capovilla, the Principal Executive Officer of the Company, hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) that:
 
 1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 2)
the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
 
 Date:    November 12, 2010
By:
/s/ Dennis F. CapovillaDennis F. CapovillaChief Executive Officer
 
 A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
**FORM 10-Q**

 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

 

(Mark one)

 
| **x** | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF** |
|-------|---------------------------------------------------------|

**THE SECURITIES EXCHANGE ACT OF 1934.**

 

**For Quarterly period ended April 1, 2006**

 

**OR**

 
| o | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF** |
|---|----------------------------------------------------------|

**THE SECURITIES EXCHANGE ACT OF 1934.**

 

**For the transition period from ____________ to ____________**

 

 
| Commission file number | 1-9751 |
|------------------------|--------|

 

 
| **CHAMPION ENTERPRISES, INC.**                         |
|--------------------------------------------------------|
| (Exact name of registrant as specified in its charter) |

 

 
| Michigan                                                       |   | 38-2743168                            |
|----------------------------------------------------------------|--------|---------------------------------------|
| (State or other jurisdiction of incorporation or organization) |   | (I.R.S. Employer

Identification No.) |

 

 
| 2701 Cambridge Court, Suite 300

Auburn Hills, MI  48326 |
|----------------------------------------------------------|
| (Address of principal executive offices)                 |

 

Registrant’s telephone number, including area code: (248) 340-9090

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
| Yes | X | No |   |
|-----|---|----|--------|

 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Exchange Act Rule 12b-2 of the Act).
| Large accelerated filer | x | Accelerated filer | o | Non-accelerated filer | o |
|-------------------------|---|-------------------|---|-----------------------|---|

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes            No     X                  

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 
|   | 76,248,977 shares of the registrant’s $1.00 par value Common Stock were outstanding as April 28, 2006. |
|--------|-------------------------------------------------------------------------------------------------------------|

 

 

----
<PAGE>   1
                              GARDEN BOTANIKA, INC.

                             CALCULATION OF EARNINGS
                     PER COMMON AND COMMON EQUIVALENT SHARE

                                  (EXHIBIT 11)
                  (AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)

<TABLE>
<CAPTION>
                                                                                            (UNAUDITED)
                                                                                         NINE MONTHS ENDED
                                                                                    --------------------------
                                                                                    OCTOBER 30,    OCTOBER 31,
                                                                                       1999           1998
                                                                                    ----------     ----------
<S>                                                                                  <C>            <C>
PRIMARY:
    Earnings --
      Net earnings (loss) applicable to common and common equivalent shares          $(17,205)      $(20,982)
                                                                                     ========       ========
   Shares --

      Weighted average common shares outstanding                                        7,069          7,069
      Net effect of stock options, based on treasury stock method using average
        market price (1)                                                                   --             --
                                                                                     --------       --------
 Weighted average common and common equivalent shares                                   7,069          7,069
                                                                                     ========       ========
Primary earnings (loss) per common and common equivalent share                       $  (2.43)      $  (2.97)
                                                                                     ========       ========
</TABLE>


FULLY DILUTED:

    Fully diluted earnings (loss) per share is not presented, as there were no
potentially dilutive securities.

NOTES:

(1)  In the calculation of weighted average common and common equivalent shares,
     nonqualified stock options and warrants to purchase common stock are
     considered common stock equivalents. Such options and warrants are
     converted using the treasury stock method, which assumes that the shares
     issuable upon exercise of the options or warrants were outstanding for the
     full period. In accordance with generally accepted accounting principles,
     no common stock equivalents are shown for the first nine months of either
     fiscal 1999 or 1998, as their effect would have been anti-dilutive.

                                       17
#### § 530.2 Purpose.

The purpose of this part is to establish conditions for extralabel use or intended extralabel use in animals by or on the lawful order of licensed veterinarians of Food and Drug Administration approved new animal drugs and approved new human drugs. Such use is limited to treatment modalities when the health of an animal is threatened or suffering or death may result from failure to treat. This section implements the Animal Medicinal Drug Use Clarification Act of 1994 (the AMDUCA) (Pub. L. 103-396).
```

[Federal Register Volume 76, Number 117 (Friday, June 17, 2011)]
[Notices]
[Page 35417]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-15299]

=======================================================================
-----------------------------------------------------------------------

COMMODITY FUTURES TRADING COMMISSION

Sunshine Act Meetings

TIME AND DATE: 10 a.m., Friday July 1, 2011.

PLACE: 1155 21st St., NW., Washington, DC, 9th Floor Commission 
Conference Room.

STATUS: Closed.

Matters To Be Considered

    Surveillance and Enforcement Matters. In the event that the times 
or dates of these or any future meetings change, an announcement of the 
change, along with the new time and place of the meeting will be posted 
on the Commission's Web site at http://www.cftc.gov.

CONTACT PERSON FOR MORE INFORMATION: Sauntia S. Warfield, 202-418-5084.

Sauntia S. Warfield,
Assistant Secretary of the Commission.
[FR Doc. 2011-15299 Filed 6-15-11; 4:15 pm]
BILLING CODE 6351-01-P
```
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          OCT-30-1999
<PERIOD-START>                             NOV-01-1998
<PERIOD-END>                               JUL-31-1999
<CASH>                                       1,185,701
<SECURITIES>                                         0
<RECEIVABLES>                                2,999,575
<ALLOWANCES>                                    61,095
<INVENTORY>                                  5,648,010
<CURRENT-ASSETS>                            10,293,570
<PP&E>                                       8,771,246
<DEPRECIATION>                               6,168,551
<TOTAL-ASSETS>                              13,659,357
<CURRENT-LIABILITIES>                        5,105,891
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                        474
<COMMON>                                        99,775
<OTHER-SE>                                   3,963,918
<TOTAL-LIABILITY-AND-EQUITY>                13,659,357
<SALES>                                      5,640,613
<TOTAL-REVENUES>                             6,266,890
<CGS>                                        4,549,621
<TOTAL-COSTS>                                4,844,628
<OTHER-EXPENSES>                             6,743,413
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             369,358
<INCOME-PRETAX>                            (5,638,122)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (5,638,122)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (6,304,216)
<EPS-BASIC>                                     (0.70)
<EPS-DILUTED>                                   (0.70)


</TABLE>
IIB 

118TH CONGRESS 

2D SESSION H. R. 7199 

IN THE SENATE OF THE UNITED STATES 

JUNE 4, 2024 

Received; read twice and referred to the Committee on Homeland Security and 

Governmental Affairs 

AN ACT 

To designate the facility of the United States Postal Service 

located at S74w16860 Janesville Road, in Muskego, Wisconsin, as the ‘‘Colonel Hans Christian Heg Post Office’’. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


ssavage on LAPJG3WLY3PROD with BILLS
2 

HR 7199 RFS

1 SECTION 1. COLONEL HANS CHRISTIAN HEG POST OFFICE. 

2 (a) DESIGNATION.—The facility of the United States 

3 Postal Service located S74w16860 Janesville Road in 

4 Muskego, Wisconsin, shall be known and designated as the 

5 ‘‘Colonel Hans Christian Heg Post Office’’. 

6 (b) REFERENCES.—Any reference in a law, map, reg7 ulation, document, paper, or other record of the United 

8 States to the facility referred to in subsection (a) shall 

9 be deemed to be a reference to the ‘‘Colonel Hans Chris10 tian Heg Post Office’’. 

Passed the House of Representatives June 3, 2024. 

Attest: KEVIN F. MCCUMBER, 

Clerk. 


ssavage on LAPJG3WLY3PROD with BILLS
§ 357.250 Labeling of cholecystokinetic drug products. ( a ) *Statement of identity.* The labeling of the product contains the established name of the drug, if any, and identifies the product as a “gallbladder diagnostic agent.”
( b ) *Indications.* The labeling of the product states, under the heading “Indications,” the following: “For the contraction of the gallbladder during diagnostic gallbladder studies.” Other truthful and nonmisleading statements, describing only the indications for use that have been established and listed in this paragraph (b), may also be used, as provided in § 330.1(c)(2), subject to the provisions of section 502 of the act relating to misbranding and the prohibition in section 301(d) of the act against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the act.
( c ) *Warnings.* [Reserved]
( d ) *Directions.* The labeling of the product contains the following statements under the heading “Directions”: ( 1 ) “Take only when instructed by a doctor:”
( 2 ) *For products containing 50-percent aqueous emulsion of corn oil.* ( i ) “Shake well before using.”
( ii ) Oral dosage is 60 milliliters 20 minutes before diagnostic gallbladder x-ray or as directed by a doctor.
( 3 ) *For products containing hydrogeneated soybean oil.* Oral dosage is 12.4 grams in a suitable, water-dispersible powder in 2 to 3 ounces of water. Stir briskly to prepare a suspension before using. Drink 20 minutes before diagnostic gallbladder x-ray or as directed by a doctor.
( e ) The word “physician” may be substituted for the word “doctor” in any of the labeling statements in this section.
[48 FR 27005, June 10, 1983, as amended at 51 FR 16267, May 1, 1986; 52 FR 7830, Mar. 13, 1987; 54 FR 8321, Feb. 28, 1989]
cc: Hon. Lidia Stiglich, District Judge 

Oldenburg Law Office 

Attorney General/Carson City 

Washoe County District Attorney 

Washoe District Court Clerk 

SUPREME COURT 

OF 

NEVADA 

(0) 1947A caP(c) 

2
Exhibit 32

 

CERTIFICATIONPURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTEDPURSUANT TO

SECTION 906OF THE SARBANES-OXLEY ACT OF 2002

 

Solely in connection with the filing of the AnnualReport of Retractable Technologies, Inc. (the “Company”) on Form 10-Kfor the period ended December 31, 2009, as filed with the United StatesSecurities and Exchange Commission on the date hereof (the “Report”), theundersigned Thomas J. Shaw, Chief Executive Officer, and Douglas W. Cowan,Chief Financial Officer, do hereby certify, pursuant to 18 U.S.C. Section 1350,as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,that:

 

(1) The Report fullycomplies with the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and

 

(2) The informationcontained in the Report fairly presents, in all material respects, thefinancial condition and results of operations of the Company.

 

Date:       March 31, 2010

 
|   | /s/ Thomas J. Shaw        |   |
|--------|---------------------------|--------|
|   | THOMAS J. SHAW            |
|   | PRESIDENT, CHAIRMAN,  AND |
|   | CHIEF EXECUTIVE OFFICER   |
|   |                      |
|   | /s/ Douglas W. Cowan      |   |
|   | DOUGLAS W. COWAN          |
|   | VICE PRESIDENT AND        |
|   | CHIEF FINANCIAL OFFICER   |

 

----
IN THE SUPREME COURT OF PENNSYLVANIA

WESTERN DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

CHARLES E. LUCAS,

Petitioner

:

:

:

:

:

:

:

:

:

:

:

No. 366 WAL 2018

Petition for Allowance of Appeal from 

the Order of the Superior Court

ORDER

PER CURIAM

AND NOW, this 13th day of February, 2019, the Petition for Allowance of Appeal

is DENIED.
<PAGE>   1
Exhibit 23.0

CONSENT AND REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANT

We hereby consent to the use on Form 10-K dated March 29, 1999, of our report
dated January 9, 1999, relating to the financial statements of VRB Bancorp.

/S/ Moss Adams, LLP

Portland, Oregon
March 23, 1999


                                       18
EERE Information Center

Programs and Offices

Search Help More Search Options

Printable Version

Small Electric Motors Notice of Proposed Rulemaking

Analytical Spreadsheets

The U.S. Department of Energy (DOE) prepared the analytical spreadsheets listed

below for the notice of proposed rulemaking stage of its energy conservation

standards rulemaking on small electric motors. Instructions on how to use the

National Impact Analysis and Manufacturer Impact Analysis spreadsheets can be

found in the appendices to the Technical Support Document.

Life Cycle Cost Spreadsheet

Small Electric Motors Life-Cycle Cost Analysis Spreadsheet (Excel 1.6 MB)

National Impact Analysis

National Impact Analysis Spreadsheet for Polyphase Small Electric Motors

(Excel 879 KB)

National Impact Analysis Spreadsheet for Single-Phase Small Electric Motors

(Excel 3.4 MB)

Manufacturer Impact Analysis

Government Regulatory Impact Model for Small Electric Motors (Excel 37 MB)

Contact Information

James Raba

Project Manager

202-586-8654

Printable Version

Building Technologies Program Home | EERE Home | U.S. Department of Energy

Webmaster | Web Site Policies | Security & Privacy | USA.gov

Content Last Updated: 11/24/2009

Appliances and Commercial Equipment Standards: Small Electric Motor... http://www1.eere.energy.gov/buildings/appliance_standards/commercial...

1 of 1 12/1/2009 7:36 AM

EERE-2007-BT-STD-0007 COMMENT 18